Marilyn Dorsey
Nurse Practitioner · Tiffin, OHNPI 1578028528
Payments from drug & device makers
Across 179 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$445
- Supernus Pharmaceuticals, Inc.$442
- Neurocrine Biosciences, Inc.$363
- Otsuka America Pharmaceutical, Inc.$335
- Johnson & Johnson$285
- AbbVie$176
- plus $974 from 10 others
What the payments were for
- Food & beverage$2,54884%
- Education$47216%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 22 | $445 |
| Supernus Pharmaceuticals, Inc. | 28 | $442 |
| Neurocrine Biosciences, Inc. | 27 | $363 |
| Otsuka America Pharmaceutical, Inc. | 23 | $335 |
| Johnson & Johnson | 14 | $285 |
| AbbVie | 11 | $176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $169 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $163 |
| Alkermes, Inc. | 8 | $123 |
| Corium, LLC | 8 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $119 |
| Vanda Pharmaceuticals Inc. | 7 | $103 |
| Lundbeck LLC | 3 | $75 |
| Indivior Inc. | 3 | $48 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Noven Therapeutics, LLC | 2 | $24 |
How this compares
$3,019 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 77 | $114,176 |
| VraylarCariprazine Hcl | 68 | $91,487 |
| Paliperidone ErPaliperidone | 123 | $40,861 |
| IngrezzaValbenazine Tosylate | 11 | $39,182 |
| Lurasidone Hcl | 145 | $17,009 |
| Asenapine Maleate | 26 | $15,911 |
| Aripiprazole | 180 | $15,133 |
| TrintellixVortioxetine Hydrobromide | 22 | $12,851 |
| Quetiapine Fumarate | 506 | $11,969 |
| Olanzapine | 406 | $11,192 |
| Divalproex Sodium ErDivalproex Sodium | 149 | $6,382 |
| Divalproex Sodium | 201 | $6,216 |
| Oxcarbazepine | 151 | $5,707 |
| Atomoxetine Hcl | 39 | $5,686 |
| Duloxetine Hcl | 169 | $5,531 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $335 | $114,17677 claims |
| AbbVieVraylar | $176 | $91,48768 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $363 | $39,18211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $163 | $12,85122 claims |
| Corium, LLCAzstarys | $119 | $4,70811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Tiffin
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.